Skip to content
No picture yet

GLN-Apremilast 30 mg – DIN 02518910

GLN-Apremilast is Apremilast 30 mg (tablet), sold in Canada. It is used for psoriatic arthritis. It is supplied by Glenmark Pharmaceuticals Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Apremilast 30 mg

Brand
GLN-Apremilast
Strength
30 mg
Used for
Psoriatic arthritis
Form
Tablet
Manufacturer
Glenmark Pharmaceuticals Canada Inc
Drug class
Phosphodiesterase 4 inhibitor
Sold in
Canada
DIN
02518910

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Apremilast pills and guides

What is Apremilast used for?

Apremilast is used for psoriatic arthritis.

Medicine type
Phosphodiesterase 4 inhibitor
Official uses from the US prescribing label

Psoriatic Arthritis

OTEZLA is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 20 kg with active psoriatic arthritis.

OTEZLA XR is indicated for the treatment of adult patients and pediatric patients 6 years of age and older and weighing at least 50 kg with active psoriatic arthritis.

Plaque Psoriasis

OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.

OTEZLA is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

OTEZLA XR is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 50 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Oral Ulcers Associated with Behçet's Disease

OTEZLA/OTEZLA XR is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease.

From the FDA-approved label on DailyMed (published Sep 11, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02518910.
  • It names GLN-Apremilast, Apremilast 30 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as GLN-Apremilast by Glenmark Pharmaceuticals Canada Inc..

In Canada: prescription only.

Ingredients

Active: Apremilast

Other Apremilast pills